FH is an inclusion criterion in 7 clinical trials for renal cell carcinoma, of which 4 are open and 3 are closed. Of the trials that contain FH status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 5 are phase 2 (4 open) [4].

FH is an inclusion criterion in 3 clinical trials for hereditary leiomyomatosis and renal cell cancer, of which 2 are open and 1 is closed. Of the trials that contain FH status and hereditary leiomyomatosis and renal cell cancer as inclusion criteria, 3 are phase 2 (2 open) [4].

FH is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 0 are open and 2 are closed. Of the trials that contain FH status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [4].

FH is an inclusion criterion in 2 clinical trials for papillary renal cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FH status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FH is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FH status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FH is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FH status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FH is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains FH status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

FH is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FH status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FH is an inclusion criterion in 1 clinical trial for paraganglioma, of which 0 are open and 1 is closed. Of the trial that contains FH status and paraganglioma as inclusion criteria, 1 is phase 2 (0 open) [4].

FH is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains FH status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].

FH is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains FH status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].